Acadia Pharmaceuticals (ACAD) Non-Current Deffered Revenue (2010 - 2012)
Acadia Pharmaceuticals (ACAD) posted quarterly Non-Current Deffered Revenue of $2.4 million for Q2 2012, down 3.02% year-over-year from $2.5 million in Q3 2011, and down 3.8% quarter-over-quarter from $2.5 million in Q1 2012.
Acadia Pharmaceuticals (ACAD) Non-Current Deffered Revenue (2010 - 2012) Analysis & Trends
Acadia Pharmaceuticals' Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $2.4 million for Q2 2012.
- In Q2 2012, Non-Current Deffered Revenue fell 3.02% year-over-year to $2.4 million; the TTM figure through Jun 2012 stood at $2.4 million (down 3.02% YoY), while the FY2011 annual figure was $2.6 million, down 1.37% from the prior year.
- Non-Current Deffered Revenue for Q2 2012 stood at $2.4 million, down from $2.5 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $2.6 million in Q4 2010, with the low at $2.4 million in Q2 2012.
- The 3-year median for Non-Current Deffered Revenue is $2.5 million (2011), against an average of $2.5 million.
- The sharpest annual moves came in 2011 and 2012: Non-Current Deffered Revenue dropped 1.37% in 2011, then dropped 3.02% in 2012.
- Acadia Pharmaceuticals' Non-Current Deffered Revenue stood at $2.6 million in 2010, then slipped by 1.37% to $2.6 million in 2011, then dropped by 7.0% to $2.4 million in 2012.
- Business Quant data shows ACAD's Non-Current Deffered Revenue at $2.4 million in Q2 2012, $2.5 million in Q1 2012, and $2.6 million in Q4 2011.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Acadia Pharmaceuticals | 4.86 Bn | 3.90 Bn | 279.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2012 | 2.41 Mn |
| Mar 31, 2012 | 2.50 Mn |
| Dec 31, 2011 | 2.59 Mn |
| Sep 30, 2011 | 2.44 Mn |
| Jun 30, 2011 | 2.48 Mn |
| Dec 31, 2010 | 2.62 Mn |